{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-038523","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2023-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.156960+00:00","generated_at":"2026-06-09T07:07:36.463391+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vivos Therapeutics implements 1-for-25 reverse stock split to meet Nasdaq minimum bid price","bullets":["Reverse stock split at 1:25 ratio effective October 25, 2023; shares reduced from ~29.9M to ~1.2M.","Common stock began trading on post-split basis on Nasdaq under same ticker VVOS on October 27, 2023.","No fractional shares issued; fractional shares rounded up to nearest whole share.","Split approved by board under stockholder authority granted at 2023 Annual Meeting on September 22, 2023.","Company aims to satisfy $1.00 minimum bid price requirement for continued Nasdaq listing under Rule 5550(a)(2)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-038523","json":"https://secwatch.observer/filing/0001493152-23-038523.json","markdown":"https://secwatch.observer/filing/0001493152-23-038523.md","text":"https://secwatch.observer/filing/0001493152-23-038523.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223038523/0001493152-23-038523-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223038523/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T07:07:36.463391+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7366270c2534d2c6c0653ce82ae1d550e11e317e","claim":"Vivos Therapeutics, Inc.: Amended certificate of incorporation to effect a 1-for-25 reverse stock split (effective 2023-10-25).","evidence_excerpt":"On October 25, 2023, Vivos Therapeutics, Inc. (the “ Company ”) filed a Certificate of Amendment to the Company’s Certificate of Incorporation with the Secretary of State of Delaware (the “ Certificate of Amendment ”) to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “ Common Stock ”) at a ratio of 1-for-25 (the “ Reverse Stock Split ”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223038523/0001493152-23-038523-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-10-25"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}